Kristopher Watson
Payments from drug & device makers
Across 277 payments — averaging $18.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$623
- Bayer$622
- AstraZeneca$612
- Novartis$430
- Novo Nordisk$421
- Lilly USA, LLC$347
- plus $2K from 20 others
What the payments were for
- Food & beverage$5,024100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 36 | $623 |
| Bayer | 33 | $622 |
| AstraZeneca | 18 | $612 |
| Novartis | 27 | $430 |
| Novo Nordisk | 26 | $421 |
| Lilly USA, LLC | 21 | $347 |
| Eisai Inc. | 12 | $247 |
| AbbVie | 14 | $227 |
| Merck | 13 | $200 |
| Otsuka America Pharmaceutical, Inc. | 8 | $179 |
| GSK | 9 | $167 |
| Boehringer Ingelheim | 10 | $159 |
| Astellas Pharma US Inc | 7 | $115 |
| Pfizer | 7 | $114 |
| Exact Sciences | 6 | $90 |
| Amarin Pharma, Inc. | 4 | $72 |
| Esperion Therapeutics, Inc. | 5 | $69 |
| Lundbeck LLC | 4 | $63 |
| Phathom Pharmaceuticals, Inc. | 5 | $62 |
| Abbott | 3 | $43 |
| Johnson & Johnson | 2 | $42 |
| Teva Pharmaceuticals USA, Inc. | 2 | $38 |
| Ardelyx, Inc. | 2 | $34 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Organon | 1 | $17 |
| Biogen | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,024 in reported general payments places this provider in the 90th percentile of 3,610 family providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 31 | $36,802 |
| OzempicSemaglutide | 21 | $34,713 |
| MounjaroTirzepatide | 33 | $34,120 |
| JardianceEmpagliflozin | 30 | $27,110 |
| KerendiaFinerenone | 23 | $23,670 |
| EliquisApixaban | 23 | $22,069 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $16,554 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $16,157 |
| FarxigaDapagliflozin Propanediol | 15 | $15,761 |
| XareltoRivaroxaban | 23 | $15,676 |
| LinzessLinaclotide | 20 | $11,790 |
| NexletolBempedoic Acid | 14 | $7,426 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 13 | $7,068 |
| Dexlansoprazole DrDexlansoprazole | 35 | $6,958 |
| Repatha SureclickEvolocumab | 12 | $5,987 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $347 | $70,92264 claims |
| Novo NordiskOzempic | $421 | $34,71321 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $159 | $34,17843 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $612 | $32,31434 claims |
| BayerKerendia | $622 | $23,67023 claims |
| PfizerEliquis | $114 | $22,06923 claims |
| GSKTrelegy Ellipta | $167 | $16,15722 claims |
| Johnson & JohnsonXarelto | $42 | $15,67623 claims |
| AbbVieLinzess | $227 | $11,79020 claims |
| Esperion Therapeutics, Inc.Nexletol | $69 | $7,42614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,610 family providers in Louisiana.
Other family in Delhi
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Brittany MillerVille Platte$158K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
- Rebekah GarrardLafayette$105K
- Tiffany RoeShreveport$97K
- Ghenet GhebretatiosBaton Rouge$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.